Sign in

    Carly Kenselaar

    Research Analyst at Citi

    Carly Kenselaar is an Equity Research Analyst at Citi specializing in the healthcare sector with a focus on biotechnology companies such as Travere Therapeutics and Krystal Biotech. She has earned recognition for her outstanding performance, maintaining a 100% success rate with an average return of over 88% on rated stocks and is ranked in the top quartile among Wall Street analysts. Kenselaar began her career in equity research prior to joining Citi, where she provides comprehensive analysis and investment recommendations in the biotech industry. She is reported to be professionally credentialed and licensed for securities research in line with industry standards.

    Carly Kenselaar's questions to Innate Pharma (IPHA) leadership

    Carly Kenselaar's questions to Innate Pharma (IPHA) leadership • Q3 2023

    Question

    Asked about the regulatory pathway for lacutamab in CTCL (Sezary syndrome and mycosis fungoides) and the development strategy and timelines for the Nectin-4 ADC program.

    Answer

    For lacutamab, the company will discuss the Sezary syndrome data with the FDA regarding a potential accelerated approval pathway, with a confirmatory Phase III trial likely to include mycosis fungoides. Further development will be pursued via partnership. For the Nectin-4 ADC, the strategy includes targeting patients post-PADCEV, leveraging a different payload (Topo I inhibitor), with an IND filing planned for the following year.

    Ask Fintool Equity Research AI